Eli Lilly and Company (LILY34) — Capital Reinvestment Ratio
Latest as of December 2025:
0.92x
Eli Lilly and Company (LILY34) has a Capital Reinvestment Ratio of 0.92x as of December 2025, meaning it reinvests 1% of its operating cash flow (R$3.22 Billion) in capital expenditures (R$2.97 Billion). See LILY34 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.92x
Capex / Operating Cash Flow
Operating Cash Flow
R$3.22 Billion
BRL
Capital Expenditures
R$2.97 Billion
BRL
Data as of
Dec 2025
Most recent filing
Eli Lilly and Company Capital Reinvestment Ratio (2014–2025)
This chart tracks Eli Lilly and Company's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Eli Lilly and Company (2014–2025)
Year-by-year Capital Reinvestment Ratio for Eli Lilly and Company from 2014 to 2025. For live market cap and broader valuation context, see Eli Lilly and Company (LILY34) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (BRL) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.65x | R$16.81 Billion | R$10.85 Billion | ▼ -32.3% |
| 2024 | 0.95x | R$8.82 Billion | R$8.40 Billion | ▼ -7.4% |
| 2023 | 1.03x | R$5.71 Billion | R$5.88 Billion | ▲ +293.1% |
| 2022 | 0.26x | R$7.08 Billion | R$1.85 Billion | ▲ +45.1% |
| 2021 | 0.18x | R$7.26 Billion | R$1.31 Billion | ▼ -42.2% |
| 2020 | 0.31x | R$6.50 Billion | R$2.03 Billion | ▲ +11.6% |
| 2019 | 0.28x | R$4.84 Billion | R$1.35 Billion | ▼ -48.8% |
| 2018 | 0.55x | R$5.52 Billion | R$3.02 Billion | ▲ +41.8% |
| 2017 | 0.39x | R$5.62 Billion | R$2.16 Billion | ▲ +71.2% |
| 2016 | 0.23x | R$4.85 Billion | R$1.09 Billion | ▼ -37.4% |
| 2015 | 0.36x | R$2.96 Billion | R$1.07 Billion | ▲ +37.9% |
| 2014 | 0.26x | R$4.46 Billion | R$1.16 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow